TABLE 1.
Patient characteristics according to LOX‐1 and CD8 status in 128 CRC patients
| Tumoral LOX‐1 score | Stromal LOX‐1 status | CD8+ CTL status | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Low | High | Low | High | Low | High | ||||
| Factors | n = 78 (%) | n = 50 (%) | P value | n = 66 (%) | n = 62 (%) | P value | n = 67 (%) | n = 61 (%) | P value |
| Sex | |||||||||
| Female | 33 (42.3) | 15 (30.0) | .192 | 25 (37.9) | 23 (37.1) | 1 | 24 (35.8) | 24 (39.3) | .717 |
| Male | 45 (57.7) | 35 (70.0) | 41 (62.1) | 39 (62.9) | 43 (64.2) | 37 (60.7) | |||
| Age | |||||||||
| ≤70 | 50 (64.1) | 36 (72.0) | .441 | 42 (63.6) | 44 (71.0) | .452 | 44 (65.7) | 42 (68.9) | .711 |
| >70 | 28 (35.9) | 14 (28.0) | 24 (36.4) | 18 (29.0) | 23 (34.3) | 19 (31.1) | |||
| T stage | |||||||||
| T0, T1 | 9 (11.5) | 4 (8.0) | .901 | 8 (12.1) | 5 (8.1) | .102 | 7 (10.4) | 6 (9.8) | .6 |
| T2 | 9 (11.5) | 5 (10.0) | 4 (6.1) | 10 (16.1) | 6 (9.0) | 8 (13.1) | |||
| T3 | 43 (55.1) | 31 (62.0) | 36 (54.5) | 38 (61.3) | 37 (55.2) | 37 (60.7) | |||
| T4 | 17 (21.8) | 10 (20.0) | 18 (27.3) | 9 (14.5) | 17 (25.4) | 10 (16.4) | |||
| N stage | |||||||||
| N0 | 39 (50.0) | 23 (46.0) | .854 | 33 (50) | 29 (46.8) | .046* | 26 (38.8) | 36 (59.0) | .066 |
| N1 | 27 (34.6) | 20 (40.0) | 19 (28.8) | 28 (45.2) | 30 (44.8) | 17 (27.9) | |||
| N2 | 12 (15.4) | 7 (14.0) | 14 (21.2) | 5 (8.1) | 11 (16.4) | 8 (13.1) | |||
| M stage | |||||||||
| M0 | 62 (79.5) | 37 (74.0) | .52 | 50 (75.8) | 49 (79.0) | .679 | 49 (73.1) | 50 (82.0) | .292 |
| M1 | 16 (20.5) | 13 (26.0) | 16 (24.2) | 13 (21.0) | 18 (26.9) | 11 (18.0) | |||
| TNM stage | |||||||||
| 0 | 3 (3.8) | 0 (0) | .762 | 3 (4.5) | 0 (0) | .498 | 1 (1.5) | 2 (3.3) | .084 |
| I | 9 (11.5) | 6 (12.0) | 7 (10.6) | 8 (12.9) | 6 (9.0) | 9 (14.8) | |||
| II | 22 (28.2) | 13 (26.0) | 18 (27.3) | 17 (27.4) | 13 (19.4) | 22 (36.1) | |||
| III | 28 (35.9) | 18 (36.0) | 22 (33.3) | 24 (38.7) | 29 (43.3) | 17 (27.9) | |||
| IV | 16 (20.5) | 13 (26.0) | 16 (24.2) | 13 (21.0) | 18 (26.9) | 11 (18.0) | |||
| Lymphatic invasion | |||||||||
| Negative | 14 (17.9) | 7 (14.0) | .631 | 10 (15.2) | 11 (17.7) | .812 | 11 (16.4) | 10 (16.4) | 1 |
| Positive | 64 (82.1) | 43 (86.0) | 56 (84.8) | 51 (82.3) | 56 (83.6) | 51 (83.6) | |||
| Venous invasion | |||||||||
| Negative | 36 (46.2) | 14 (28.0) | .043* | 29 (43.9) | 21 (33.9) | .279 | 24 (25.8) | 26 (42.6) | .471 |
| Positive | 42 (53.8) | 36 (72.0) | 37 (56.1) | 41 (66.1) | 43 (64.2) | 35 (57.4) | |||
| Histological grade | |||||||||
| Well | 21 (26.9) | 15 (30.0) | .484 | 18 (27.3) | 18 (29.0) | .478 | 19 (28.4) | 17 (27.9) | .988 |
| Moderately | 49 (62.8) | 33 (66.0) | 41 (62.1) | 41 (66.1) | 43 (64.2) | 39 (63.9) | |||
| Others | 8 (10.3) | 2 (4.0) | 7 (10.6) | 3 (4.8) | 5 (7.5) | 5 (8.2) | |||
| KRAS variant | |||||||||
| Wild | 27 (62.8) | 27 (60.0) | .829 | 30 (66.7) | 28 (59.6) | .523 | 23 (56.1) | 31 (66.0) | .385 |
| Mutation | 16 (37.2) | 18 (40.0) | 15 (33.3) | 19 (40.4) | 18 (43.9) | 16 (34.0) | |||
| BRAF variant | |||||||||
| Wild | 41 (95.3) | 44 (97.8) | .612 | 41 (91.1) | 46 (97.9) | .198 | 40 (97.6) | 45 (95.7) | 1 |
| Mutation | 2 (4.7) | 1 (2.2) | 4 (8.9) | 1 (2.1) | 1 (2.4) | 2 (4.3) | |||
Abbreviations: tumoral LOX‐1 score‐L, 0–3; tumoral LOX‐1 score‐H, 4; stromal LOX‐1‐L, ≤534.4 mm2; stromal LOX‐1, >534.4/mm2; CD8+ CTL‐L, ≤103.4/mm2; CD8+ CTL‐H, >103.4/mm2.
*
P < .05 is considered statistically significant. p‐values were calculated from Fisher's exact tests and chi‐square tests.